Gastro-Intestinal Disorder

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Gastro-Intestinal Disorder is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

22/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Terminated2 · 22%

No longer available2 · 22%

Unknown status2 · 22%

Recruiting2 · 22%

Completed1 · 11%

Clinical Trials

Trial Activity

9 trials

Domperidone in Treating Patients With Gastrointestinal Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT01696734·200 enrolled

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

Recruiting·UUniversity of Nottingham·N/A·NCT06956703·240 enrolled

Localized Therapeutics for the Treatment of Gastrointestinal Disorders II

Completed·SStanford University·Phase 1·NCT02745678·3 enrolled

Domperidone for Relief of Gastrointestinal Disorders

Terminated·CCarle Physician Group·N/A·NCT00761254·42 enrolled

Sirolimus for Eosinophil-Associated Gastrointestinal Disorders

Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01814059·4 enrolled

Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders

No longer available·—·N/A·NCT02567175

Use of Domperidone for Treatment of Upper Gastrointestinal Disorders

No longer available·PPalo Alto Medical Foundation·N/A·NCT03128398

Domperidone for Refractory Gastrointestinal Disorders

Unknown status·—·N/A·NCT00777439·75 enrolled

Probiotics in GastroIntestinal Disorders

Unknown status·UUniversity College Cork·Phase 2/3·NCT00510978·360 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)